BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1347 related articles for article (PubMed ID: 10789823)

  • 1. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy and cardiotoxicity].
    Brestescher C; Pautier P; Farge D
    Ann Cardiol Angeiol (Paris); 1995 Oct; 44(8):443-7. PubMed ID: 8669796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
    Gharib MI; Burnett AK
    Eur J Heart Fail; 2002 Jun; 4(3):235-42. PubMed ID: 12034146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline cardiotoxicity.
    Jones RL; Swanton C; Ewer MS
    Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
    Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
    J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
    Chia PL; Chiang K; Snyder R; Dowling A
    J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity and cardioprotection during chemotherapy.
    Hochster H; Wasserheit C; Speyer J
    Curr Opin Oncol; 1995 Jul; 7(4):304-9. PubMed ID: 7578376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
    Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
    Madeddu C; Deidda M; Piras A; Cadeddu C; Demurtas L; Puzzoni M; Piscopo G; Scartozzi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e12-e18. PubMed ID: 27755238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cardiac toxicity of cancer chemotherapy].
    Sequeira JF; Madruga IM; Ribeiro M; Duarte PC; Ferreira DC; Sarmento JL
    Acta Med Port; 1994 May; 7(5):311-8. PubMed ID: 8073908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.